Study Explains Why DNA Damage from Smoking or UV Causes Cancer in Some

Scientists have uncovered direct evidence that inherited genetics can steer how cancers emerge and evolve, even after the same environmental DNA insult. The work, reported in Nature from experiments in mice, shows that germline variation and acquired mutations jointly determine the eventual evolutionary “route” a tumor takes.

Instead of treating inherited risk as a background factor, the study links it to the mechanics of mutation and signaling. Tumors develop when DNA damage accumulates, producing mutations that let cells ignore growth-control cues and evade death signals.

A key challenge in humans has been separating genetic effects from messy differences in lifestyle and exposure history. Even within the same risk setting, only some individuals develop cancer—while others do not—suggesting that inherited genetics can buffer or amplify the consequences of DNA damage.

To isolate the variable, researchers bred four mouse strains with genetic diversity comparable to that found across human populations. Every animal received an identical single dose of the liver carcinogen diethylnitrosamine (DEN) at a fixed age, removing differences in dose, timing, and environment.

The team then sequenced nearly 600 tumors and profiled gene activity, comparing them with untreated controls. With these data, they reconstructed tumor histories from the initial cancer-causing mutation to the later genomic and transcriptional states.

Across strains, tumors repeatedly converged on a shared cancer-promoting outcome: activation of the MAPK signaling pathway. Yet convergence did not mean sameness. Depending on inherited background, the specific driver mutation differed, reshaping other signaling circuits engaged during progression.

One striking divergence was the tendency for whole-genome duplication, where an entire chromosome set is doubled. This event can accelerate evolution by providing extra genetic material for selection, potentially altering how rapidly malignant cells adapt.

The findings suggest that DNA-damaging therapies may not affect all patients identically. If inherited genetics influences both mutation trajectories and pathway choices, then treatment response could vary in ways not captured by standard clinical variables.

“Our results show for the first time how genetic background influences the mutation processes and the pathways leading to tumor development,” the researchers conclude. They argue that future prevention, screening, and precision oncology should incorporate population diversity and inherited genomic context to improve targeting and prognostic power.